Early-stage drug candidate diminishes deficits in Parkinson's disease

University of Utah Health scientists have identified a molecule that slows cells' production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson's disease. Its discovery points toward a new strategy for treating the disease and potentially stopping its progression.

source https://medicalxpress.com/news/2021-09-early-stage-drug-candidate-diminishes-deficits.html